Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BIO-TECHNE CORPORATION

(TECH)
  Report
Delayed Nasdaq  -  04:00 2022-11-29 pm EST
327.07 USD   -1.01%
11/28BIO-TECHNE TO PRESENT AT THE FIFTH ANNUAL EVERCORE ISI HealthCONx CONFERENCE
PR
11/17Transcript : Bio-Techne Corporation Presents at Stephens Annual Investment Conference 2022, Nov-17-2022 11:00 AM
CI
11/17Namocell Highlighted in Nature Publication for Efficient Single Cell Cloning of Human Pluripotent Stem Cells
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Bio-Techne Files Lawsuit in UK Against Molecular Instruments for Patent Infringement

09/26/2022 | 09:17am EST


ę MT Newswires 2022
All news about BIO-TECHNE CORPORATION
11/28BIO-TECHNE TO PRESENT AT THE FIFTH ANNUAL EVERCORE ISI HealthCONx CONFERENCE
PR
11/17Transcript : Bio-Techne Corporation Presents at Stephens Annual Investment Co..
CI
11/17Namocell Highlighted in Nature Publication for Efficient Single Cell Cloning of Human P..
CI
11/17Namocell highlighted in nature publication for efficient single cell cloning of human p..
PR
11/15Transcript : Bio-Techne Corporation Presents at Stifel 2022 Healthcare Confer..
CI
11/15Bio-Techne Opens New Manufacturing Facility in Connecticut
MT
11/15Bio-techne announces opening of new immunoassay manufacturing facility
PR
11/15Bio-Techne Announces Opening of New Immunoassay Manufacturing Facility
CI
11/10Bio-techne to present at the stephens annual investment conference
PR
11/10BIO-TECHNE CORPORATION : Ex-dividend day for
FA
More news
Analyst Recommendations on BIO-TECHNE CORPORATION
More recommendations
Financials (USD)
Sales 2023 1 202 M - -
Net income 2023 293 M - -
Net cash 2023 176 M - -
P/E ratio 2023 46,4x
Yield 2023 0,54%
Capitalization 12 835 M 12 835 M -
EV / Sales 2023 10,5x
EV / Sales 2024 9,10x
Nbr of Employees 3 000
Free-Float 99,2%
Chart BIO-TECHNE CORPORATION
Duration : Period :
Bio-Techne Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIO-TECHNE CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 327,07 $
Average target price 420,32 $
Spread / Average Target 28,5%
EPS Revisions
Managers and Directors
Charles R. Kummeth President, Chief Executive Officer & Director
James T. Hippel Chief Financial Officer
Robert V. Baumgartner Chairman
Brenda Swierenga Furlow Secretary & Chief Compliance Officer
Randolph C. Steer Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BIO-TECHNE CORPORATION-36.13%12 966
MODERNA, INC.-30.95%67 378
IQVIA HOLDINGS INC.-23.99%39 832
LONZA GROUP AG-34.32%39 180
ALNYLAM PHARMACEUTICALS, INC.23.36%25 738
SEAGEN INC.-21.59%22 506